Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
Receptor-interacting protein 1 (RIPK1) |
Target Info
|
Inhibitor |
[2] |
| References |
Top |
| REF 1 |
ClinicalTrials.gov (NCT03681951) First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors. U.S. National Institutes of Health.
|
| REF 2 |
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
